Fluorescence Imaging Technology for Small-Incision Endocrine and Lymphatic Procedures

Getinge launched the Fluobeam LS, a fluorescence imaging system developed to assist surgeons operating within access and visibility constraints during small-incision procedures. The optical visualization device integrates into surgical workflows to support intraoperative decision-making by identifying difficult-to-distinguish anatomical structures, focusing primarily on clinical applications in thyroid surgery and sentinel lymph node detection during breast cancer operations.

Optical Hardware and Operating Room Integration
The imaging hardware addresses the physical restrictions of operating in confined anatomical spaces. The device incorporates an ergonomic optical head that can be positioned close to the surgical cavity without obstructing the primary line of sight. Control of the imaging functions is managed through an integrated joystick, allowing operators to adjust the field of view directly from the sterile field.

The optical platform generates high-definition imaging outputs combined with quantitative assessment software tools. These integrated acquisition modes process visual data in real-time, providing surgeons with objective physiological insights to support tissue preservation and excision protocols.

Tissue Differentiation in Thyroid and Lymphatic Operations
In the application of thyroid surgery, the accurate identification and preservation of parathyroid glands is a critical procedural step necessary to prevent postoperative complications such as hypocalcemia. The optical device utilizes fluorescence imaging mechanisms to enhance tissue differentiation, permitting surgeons to objectively assess parathyroid perfusion rates and viability during the excision sequence.

For breast cancer oncology, the system is deployed for sentinel lymph node detection. Conventional tracing techniques are often limited by low visibility when executed through small surgical openings. The fluorescence tracking provides distinct visual mapping of lymphatic pathways despite restricted incision sizes, supporting the accurate localization and extraction of target nodes.

Regulatory Status and Industry Presentation
The intraoperative imaging system holds a CE mark, clearing the technology for commercial distribution across European medical device markets. The hardware was formally presented to the medical community at the Congress of the European Society of Endocrine Surgeons in Geneva, Switzerland, in May 2026, demonstrating the clinical integration of fluorescence-guided techniques in modern endocrine procedures.

Additional Context:
This section details technical specifications and competitive benchmarking not included in the original product announcement

Near-infrared fluorescence imaging systems are evaluated across the medical device industry based on their excitation wavelengths, tissue penetration depth, and real-time contrast capabilities. In contrast to conventional radiocolloid mapping or blue dye injection for sentinel lymph node detection, near-infrared fluorescence imaging eliminates ionizing radiation exposure for both the patient and the surgical staff while maintaining statistically comparable node detection rates.

When measured against heavy, cart-based imaging platforms, handheld or articulated arm configurations offer a measurable reduction in spatial footprint within crowded operating rooms. Objective benchmark criteria for intraoperative visualization systems include the focal working distance from the surgical cavity, ambient light interference rejection, and the software's capacity to quantify tissue perfusion metrics directly on the integrated display rather than relying solely on subjective visual interpretation.

Edited by Natania Lyngdoh, Induportals editor, assisted by AI.

www.getinge.com